2022
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
Zeidan AM, Platzbecker U, Garcia-Manero G, Sekeres MA, Fenaux P, DeZern AE, Greenberg PL, Savona MR, Jurcic JG, Verma A, Mufti G, Buckstein R, Santini V, Shetty JK, Ito R, Zhang J, Zhang G, Ha X, Backstrom JT, Komrokji RS. Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood 2022, 140: 2170-2174. PMID: 35797468, PMCID: PMC10653038, DOI: 10.1182/blood.2022016171.Peer-Reviewed Original ResearchConceptsLower-risk myelodysplastic syndromesLow-risk myelodysplasiaErythropoiesis-stimulating agentsEligible patientsTransfusion independenceMyelodysplastic syndromeLong-term benefitsLuspaterceptMedian durabilityRing sideroblastsPatientsIncremental benefitPlaceboSignificant minorityTherapyTransfusionMyelodysplasiaSideroblastsSyndromeTrialsWeeksMonths
2021
Peri‐transfusion quality‐of‐life assessment for patients with myelodysplastic syndromes
Abel GA, Klepin HD, Magnavita ES, Jaung T, Lu W, Shallis RM, Hantel A, Bahl NE, Dellinger‐Johnson R, Winer ES, Zeidan AM. Peri‐transfusion quality‐of‐life assessment for patients with myelodysplastic syndromes. Transfusion 2021, 61: 2830-2836. PMID: 34251040, DOI: 10.1111/trf.16584.Peer-Reviewed Original ResearchConceptsRed cell transfusionCell transfusionMyelodysplastic syndromeFollow-up questionnaireTransfusion decisionsQoL assessmentProportion of patientsProspective pilot studyQoL 1Repeat transfusionHemoglobin levelsPatients' qualityScore 7TransfusionPatientsStudy designQoLPilot studySignificant increaseSyndromeLife assessmentSignificant changesDaysQuestionnaireAssessment
2020
MDS-280: Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients with Lower-Risk MDS (LR-MDS) with Ring Sideroblasts (RS)
Komrokji R, Sekeres M, Zeidan A, Fenaux P, Platzbecker U, DeZern A, Greenberg P, Savona M, Jurcic J, Verma A, Mufti G, Buckstein R, Santini V, Laadem A, Ito R, Zhang J, Louis C, Linde P, Garcia-Manero G. MDS-280: Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients with Lower-Risk MDS (LR-MDS) with Ring Sideroblasts (RS). Clinical Lymphoma Myeloma & Leukemia 2020, 20: s322. DOI: 10.1016/s2152-2650(20)30979-4.Peer-Reviewed Original ResearchLonger-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS).
Komrokji R, Sekeres M, Zeidan A, Fenaux P, List A, Dezern A, Greenberg P, Savona M, Jurcic J, Verma A, Mufti G, Buckstein R, Santini V, Laadem A, Ito R, Zhang J, Louis C, Linde P, Garcia-Manero G. Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS). Journal Of Clinical Oncology 2020, 38: 7518-7518. DOI: 10.1200/jco.2020.38.15_suppl.7518.Peer-Reviewed Original ResearchLow-risk MDSPBO armRing sideroblastsWeek 1Transfusion visitRBC transfusionSerum ferritinWeek 33Week 9Mean numberClass erythroid maturation agentRBC unitsBurden reductionPhase 3 trialLower-risk MDSErythroid maturation agentTransfusion reductionMaturation agentsTransfusion eventsClinical efficacyL vsLuspaterceptResponse episodesWeeksTransfusion
2019
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leukemia & Lymphoma 2019, 60: 3181-3187. PMID: 31170846, DOI: 10.1080/10428194.2019.1622700.Peer-Reviewed Original ResearchConceptsRBC transfusion independenceLR-MDS patientsTransfusion independenceHMA initiationRBC transfusionClinical effectivenessReal-life clinical effectivenessRed blood cell transfusionLower-risk myelodysplastic syndromesLow-risk MDS patientsRisk MDS patientsBlood cell transfusionRisk myelodysplastic syndromesHMA therapyLR-MDSCell transfusionMost patientsDisease courseMDS patientsMedicare databaseMyelodysplastic syndromePopulation-level estimatesLower oddsTransfusionPatients
2014
An update on type 2B von Willebrand disease
Mikhail S, Aldin ES, Streiff M, Zeidan A. An update on type 2B von Willebrand disease. Expert Review Of Hematology 2014, 7: 217-231. PMID: 24521271, DOI: 10.1586/17474086.2014.868771.Peer-Reviewed Original ResearchConceptsVon Willebrand diseaseType 2B von Willebrand diseaseVon Willebrand factorAbnormal von Willebrand factorWillebrand diseaseHigh molecular weight VWF multimersSignificant clinical variationWeight VWF multimersPlatelet countPlatelet transfusionsReplacement therapyPlatelet clearanceVWD patientsTransient decreaseClinical variationFactor VIIIWillebrand factorDiseaseVWF multimersPatientsIdentical mutationsSuboptimal resultsTransfusionDesmopressinPreferential loss